Coronavirus Disease 2019–COVID-19
Top Cited Papers
Open Access
- 16 September 2020
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 33 (4)
- https://doi.org/10.1128/cmr.00028-20
Abstract
In recent decades, several new diseases have emerged in different geographical areas, with pathogens including Ebola virus, Zika virus, Nipah virus, and coronaviruses (CoVs). Recently, a new type of viral infection emerged in Wuhan City, China, and initial genomic sequencing data of this virus do not match with previously sequenced CoVs, suggesting a novel CoV strain (2019-nCoV), which has now been termed severe acute respiratory syndrome CoV-2 (SARS-CoV-2). Although coronavirus disease 2019 (COVID-19) is suspected to originate from an animal host (zoonotic origin) followed by human-to-human transmission, the possibility of other routes should not be ruled out. Compared to diseases caused by previously known human CoVs, COVID-19 shows less severe pathogenesis but higher transmission competence, as is evident from the continuously increasing number of confirmed cases globally. Compared to other emerging viruses, such as Ebola virus, avian H7N9, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has shown relatively low pathogenicity and moderate transmissibility. Codon usage studies suggest that this novel virus has been transferred from an animal source, such as bats. Early diagnosis by real-time PCR and next-generation sequencing has facilitated the identification of the pathogen at an early stage. Since no antiviral drug or vaccine exists to treat or prevent SARS-CoV-2, potential therapeutic strategies that are currently being evaluated predominantly stem from previous experience with treating SARS-CoV, MERS-CoV, and other emerging viral diseases. In this review, we address epidemiological, diagnostic, clinical, and therapeutic aspects, including perspectives of vaccines and preventive measures that have already been globally recommended to counter this pandemic virus.Keywords
Other Versions
This publication has 346 references indexed in Scilit:
- Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and DeltacoronavirusJournal of Virology, 2012
- Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?Clinical Microbiology Reviews, 2012
- A Conserved Domain in the Coronavirus Membrane Protein Tail Is Important for Virus AssemblyJournal of Virology, 2010
- Identification of In Vivo-Interacting Domains of the Murine Coronavirus Nucleocapsid ProteinJournal of Virology, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian HamstersJournal of Virology, 2008
- Animal models and vaccines for SARS-CoV infectionVirus Research, 2008
- Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging InfectionClinical Microbiology Reviews, 2007
- Emerging Respiratory Viruses: Challenges and Vaccine StrategiesClinical Microbiology Reviews, 2006
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004